Akt-activated endothelium constitute the niche for residual disease and resistance to bevacizumab in ovarian cancer

作者
Bella Samia Guerrouahen,Jennifer Pasquier,Nadine Abu-Kaoud,Mahtab Maleki,Pegah Ghiabi,Ahmad Saleh,Arash Rafii
出处
期刊:Qatar Foundation Annual Research Forum Volume 2012 Issue 1
标识
DOI:10.5339/qfarf.2012.bmo7
摘要

Background: Ovarian cancer is the second leading cause of cancer-related death in women worldwide. Despite optimal cytoreduction and adequate adjuvant therapy, many patients will experience disease recurrence. Targeted therapies have been evaluated in ovarian cancer as a method to overcome resistant disease. Antiangiogenic therapy such as bevacizumab (Avastin; Genentech) has limited efficacy. Indeed, it increases hypoxia, drug resistance and, tumor rebound phenomenon observed after withdrawal. Hypothesis: We hypothesized that abnormalities in the tumor endothelium contribute to tumor growth which may be a direct source for chemotactic factors and might be responsible for residual microscopic disease and rebound effect following antiangiogenic treatment. Methods: Using a feeder-free Matrigel and spheroid models of ovarian cancer, we examined the effect of bevacizumab on residual disease. We used Akt-activated endothelial cells (EC) that replicates tumor endothelial biology and controls tumor growth, and human umbilical vein endothelial cells (HUVEC) to investigate the antiangiogenic activity of bevacizumab by angiogenesis and migration assays. We conducted an XTT assay to examine the effect of bevacizumab on proliferation of vascular endothelial growth factor (VEGF) producing human ovarian cancer cell lines. Finally, expression of FGF-2, phospho-Akt was assessed by Western blotting and flow cytometry. Results: We demonstrated the role of Akt-activated ECs in supporting expansion and self-renewal of ovarian cancer cells (OCC) in a residual disease context. We demonstrated that OCCs activate the endothelium, which displays resistance to bevacizumab. Bevacizumab had no effect on the proliferation of Akt-activated ECs, but significantly inhibited angiogenesis and delayed wound healing in HUVEC. We demonstrated that in this setting the cross-talk between cancer cells and ECs activates Pi3k/Akt inducing an autocrine loop through the pro-angiogenic factor fibroblast growth factor-2 (FGF-2) bypassing the VEGF-R pathway. We demonstrated that FGF-2 blocking would efficiently reverse the resistance to bevacizumab. Conclusion: Our data highlights the role of an activated endothelium in the constitution of the residual disease and resistance to bevacizumab. These results hint on the concept of using combination therapy to override drug resistance in ovarian cancer and to suppress or eradicate residual disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
dycq完成签到,获得积分10
刚刚
HaohaoLi完成签到,获得积分10
刚刚
勤奋笙完成签到,获得积分10
刚刚
所所的应助被xiaowang采纳,获得10
刚刚
uizomd完成签到,获得积分10
1秒前
闹闹完成签到 ,获得积分10
1秒前
小A完成签到,获得积分10
1秒前
山野完成签到,获得积分10
1秒前
1秒前
无穷爱科研完成签到,获得积分10
1秒前
ren完成签到,获得积分10
2秒前
tyughi完成签到,获得积分10
2秒前
Young完成签到,获得积分10
2秒前
2秒前
9202211125完成签到,获得积分10
3秒前
3秒前
3秒前
123完成签到,获得积分10
3秒前
海绵研研完成签到 ,获得积分10
3秒前
Inter09完成签到,获得积分10
3秒前
arniu2008发布了新的文献求助10
3秒前
乖乖羊完成签到,获得积分10
4秒前
binbin完成签到,获得积分10
5秒前
流觞俊秀完成签到 ,获得积分10
5秒前
负责的紫安完成签到 ,获得积分10
5秒前
5秒前
博士搏斗完成签到 ,获得积分10
6秒前
海燕完成签到 ,获得积分10
6秒前
马格发布了新的文献求助10
7秒前
7秒前
澪617完成签到,获得积分10
7秒前
无极微光的应助被叫我第一名采纳,获得20
7秒前
Xiaoyan完成签到,获得积分10
8秒前
小圆子完成签到,获得积分10
8秒前
alei1203完成签到,获得积分10
8秒前
8秒前
一氧化二氢完成签到,获得积分10
8秒前
帆子完成签到 ,获得积分10
9秒前
zhanga发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173580
求助须知:如何正确求助?哪些是违规求助? 9565737
关于积分的说明 21782083
捐赠科研通 7767775
什么是DOI,文献DOI怎么找? 3431604
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476870